Protalix BioTherapeutics (PLX) Common Equity (2010 - 2026)

Protalix BioTherapeutics has reported Common Equity for 17 years, with the latest figure at $67.2 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 48.71% year-over-year to $67.2 million; the trailing twelve-month figure through Mar 2026 stood at $67.2 million (up 48.71% YoY), and the FY2025 full-year result was $48.2 million, up 11.62% from the prior year.
• Common Equity for Q1 2026 stood at $67.2 million, up from $48.2 million in the prior quarter.
• The five-year high for Common Equity was $67.2 million in Q1 2026, with the low at -$11.5 million in Q3 2022.
• Average Common Equity over 5 years is $27.6 million, with a median of $33.6 million recorded in 2023.
• Year-over-year, Common Equity tumbled 5505.63% in 2022 and jumped 2854.96% in 2024.
• Tracing PLX's Common Equity over 5 years: stood at -$10.6 million in 2022, then jumped by 415.5% to $33.6 million in 2023, then gained by 28.72% to $43.2 million in 2024, then advanced by 11.62% to $48.2 million in 2025, then surged by 39.39% to $67.2 million in 2026.
• The last three Common Equity figures came in at $67.2 million (Q1 2026), $48.2 million (Q4 2025), and $52.9 million (Q3 2025), per Business Quant data.

Peer Comparison